Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (28) clinical trials

A clinical trial to evaluate treatments using Pembrolizumab for patients with Adrenocortical carcinoma

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.


Patients are needed to participate in a clinical research study for the treatment of Ductal Carcinoma In Situ, Postmenopausal

PRIMARY OBJECTIVES; I. To assess whether CE/BZA (conjugated estrogens/bazedoxifene) for 28 days +/- 7 days reduces proliferation as measured by marker of proliferation Ki-67 (Ki-67) protein expression. SECONDARY OBJECTIVES: I. To assess whether CE/BZA alters markers associated with progression to invasive cancer (abrogated response to cellular stress [ARCS] signature) in ...


A clinical research study of S-1 de-escalation, Chemotherapy by Investigator's choice for the treatment of Esophageal Adenocarcinoma, Gastric Cancer, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Gastric Adenocarcinoma

Open-label, multi-center, controlled, randomized, parallel-group phase II trial in patients with metastatic esophagogastric cancer having received induction chemotherapy. Patients will be registered before or after application of a three-months induction chemotherapy . This 12-week induction therapy will consist of one of the following regimens: FLO/mod. Folfox-6, Cisplatin/5-FU, Cisplatin/S-1, FLOT, EOX/EOF ...


A clinical trial to evaluate treatments for patients with Postmenopausal, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Adenocarcinoma, Atypical Hyperplasia

PRIMARY OBJECTIVES: I. To determine if there is a decrease in proliferation index, measured by Ki-67 expression, in complex atypical hyperplasia (CAH)/endometrial intraepithelial neoplasia (EIN) or grade 1 endometrial cancer cells from baseline to post-exemestane treatment. SECONDARY OBJECTIVES: I. Circulating serum estradiol and progesterone. II. Pathological response (regression of CAH/EIN ...


A clinical trial sponsored by National Cancer Institute (NCI) for a research study of Veliparib, Gemcitabine Hydrochloride, Cisplatin

PRIMARY OBJECTIVES: I. To optimize the dose of veliparib combined with fixed doses of gemcitabine hydrochloride (gemcitabine) and cisplatin in a (non-randomized, lead-in portion of Part I). II. To evaluate the response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria) of gemcitabine, cisplatin, and veliparib (Arm A) and gemcitabine, ...


Patients are needed to participate in a clinical research study for the treatment of Renal Cell Carcinoma

Background Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, ...


A clinical trial sponsored by Eisai Inc. for a research study for the treatment of Renal Cell Carcinoma

Study E7080-G000-218 is a Randomized, Double-blind, Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared ...


A clinical trial sponsored by Washington University School of Medicine for a research study of Irinotecan, Ramucirumab

The investigators hypothesize that this combination regimen of irinotecan plus ramucirumab administered as second line treatment will be tolerated and lead to improved outcomes similar to paclitaxel plus ramucirumab in patients with advanced gastric and gastro-esophageal junction (GEJ) cancers. This study proposes a phase II clinical trial with irinotecan plus ...